Investors should consider Hims & Hers Health (HIMS) as a high-conviction "deep value" play, especially following a significant $1.2 million insider purchase by a board member. The company is positioned for 32% forward growth by leveraging a subscription-based model and expanding into the high-demand compounded GLP-1 weight loss market. While pure-play AI hardware stocks like Micron (MU) appear overheated, HIMS offers a more attractive valuation at an EV/GP/RG of 0.1 while integrating AI for lab diagnostics. Look to capitalize on the broader Longevity trend by investing in platforms that bridge the gap between wearable tech, affordable lab testing, and personalized medicine. Exercise caution with high-momentum AI stocks that have seen multi-fold increases, and instead rotate capital into "AI-enabled" companies trading at more reasonable multiples.

Hims & Hers Health, Inc. (HIMS)

• Insider Activity: A director (board member) recently purchased $1.2 million worth of stock. This is noted as the first insider buy in two years. • The speaker emphasizes that while insider sales can happen for many reasons (taxes, tuition), insiders generally only buy when they believe the stock price will increase. • Valuation Metrics: The stock is described as "deep value" compared to overheated AI momentum stocks. • EV/GP/RG (Enterprise Value to Gross Profit to Revenue Growth): 0.1 • Forward Growth: Predicted to grow 32% over the next 12 months. • Gross Margin: 74% • EBITDA Margin: 14% • Current Price Mentioned: Approximately $25 per share. • Business Model: Described as a "SaaS business in disguise" (Software as a Service) because it operates on a subscription model without the complications of traditional insurance. • GLP-1 & Compounding: The company is expanding its weight-loss offerings. • Launching compounded GLP-1s in Canada. • The CEO (Andrew Dudum) is reportedly micro-dosing GLP-1s for longevity and health optimization rather than just weight loss. • The speaker views "compounding" as the future of personalized medicine (custom dosages tailored by AI). • AI Integration: • Potential for "AI-only doctors" to serve the platform's 2.4 million customers as regulations evolve. • AI is currently being used to interpret lab results. • Product Expansion: The company is moving into biological age tracking and affordable lab testing ($299 for twice-a-year labs).

Takeaways

• Monitor Insider Confidence: The $1.2 million buy from a board member suggests internal confidence in the company's near-term prospects or current undervaluation. • Sector Play: HIMS offers exposure to both the Telehealth and Weight Loss (GLP-1) sectors, but at a valuation the speaker considers much lower than traditional "hot" tech stocks. • Personalized Medicine Trend: Investors should watch the company's ability to scale its "compounding" (customized drug) model, as this represents a shift toward high-margin, personalized healthcare. • Regulatory Risk/Opportunity: The future growth of the platform heavily depends on the regulatory approval of AI-driven prescriptions and the continued legality/patent status of compounded medications.

AI Momentum Stocks (General Sector)

• The speaker expresses concern that the broader market is only rewarding "overheated" AI stocks. • Micron (MU) was specifically mentioned as a stock that has moved "too fast" and may be getting ahead of itself. • The sentiment is bearish on the current valuations of high-momentum AI stocks, suggesting they are becoming "ridiculous" compared to value-oriented innovative companies.

Takeaways

• Exercise Caution: Be wary of chasing "momentum" in AI stocks that have seen multi-fold increases (e.g., 7x gains) in short periods. • Rotation Strategy: Consider looking for "AI-enabled" companies (like HIMS) that trade at lower valuations but still benefit from AI integration, rather than buying pure-play hardware or chip stocks at peak prices.

Healthcare & Longevity Themes

• Lab-Based Diagnostics: The speaker views regular blood labs as the "replacement of the physical" exam. Companies providing low-cost, AI-interpreted diagnostics are positioned for growth. • Heart Disease Prevention: There is a bullish outlook on the intersection of wearables and AI to predict heart attacks and manage cardiovascular health, potentially making heart disease a "non-issue" in the future.

Takeaways

• Investment Theme: Look for opportunities in companies that bridge the gap between consumer tech (wearables) and clinical data (labs). • Longevity Market: The shift of GLP-1 drugs from "diabetes/obesity only" to "longevity and optimization" tools suggests a much larger total addressable market (TAM) than currently priced into many healthcare stocks.